Showing 81 - 100 results of 18,495 for search '(( significantly ((weaker decrease) OR (teer decrease)) ) OR ( significantly improve decrease ))*', query time: 0.50s Refine Results
  1. 81

    Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy by Yuhao Hao (16938532)

    Published 2023
    “…The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. …”
  2. 82

    Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy by Yuhao Hao (16938532)

    Published 2023
    “…The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. …”
  3. 83

    Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy by Yuhao Hao (16938532)

    Published 2023
    “…The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. …”
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89
  10. 90

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  11. 91

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  12. 92

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  13. 93

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”
  14. 94

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”
  15. 95

    Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

    Published 2021
    “…<b><i>Results:</i></b> Mean number of attacks/month significantly decreased (95% credible interval [CrI] excluding 0) from 1.15 preintervention to 0.25 and 0.23, 8 and 14 months within intervention, with mean decreases of −0.89 (95% CrI: −1.21 to −0.58) and −0.92 (95% CrI: −1.22 to −0.60), respectively. …”
  16. 96

    Changes in TEER and permeability of EA.hy926 cells exposed to EVs or pellets from infected or uninfected macrophages. by Myriam Lucia Velandia-Romero (8259726)

    Published 2020
    “…Interestingly, TEER increased significantly (up to 15 Ω/cm<sup>2</sup>) when EA.hy926 cells were exposed to EVs obtained from infected U937 macrophages (<i>EV (+)</i><sub><i>4G2</i></sub> or <i>P(+))</i> (B). …”
  17. 97
  18. 98
  19. 99
  20. 100